Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.

ABSTRACT:

Background

Emerging evidence suggests that cutaneous immune-related adverse events (cirAEs) are associated with a survival benefit in the setting of advanced melanoma treated with immune checkpoint inhibitor (ICI) therapy. Previous studies have not examined the role of melanoma subtypes on cirAE development and downstream therapeutic outcomes.

Objective

Examine the impact of melanoma subtypes on cirAE onset and survival among ICI recipients.

Methods

Retrospective multi-institutional cohort study. Multivariate time-series regressions were utilized to assess relationships between melanoma subtype, cirAE development, and survival.

Results

Among 747 ICI recipients, 236 (31.6%) patients developed a cirAE. Patients with acral melanoma were less likely to develop a ci

SUBMITTER: Nguyen N 

PROVIDER: S-EPMC10260279 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature